Affiliation:
1. Moscow Regional Research and Clinical Institute (MONIKI)
Abstract
Over the past 25 years, Xalatan (Latanaprost) has become one of the most effective first-line drugs in the treatment of glaucoma, due to its pronounced hypotensive effect, safety and convenience of a single instillation. The review article presents the historical aspects of the creation and mechanisms of action of prostaglandin analogs, the neuroprotective properties of latanoprost, as well as data from meta-analyses and clinical studies on the effectiveness of the drug in the treatment of glaucoma.
Publisher
PE Polunina Elizareta Gennadievna
Reference74 articles.
1. Senjam SS. Glaucoma blindness-A rapidly emerging non-communicable ocular disease in India: Addressing the issue with advocacy. J Family Med Prim Care. 2020 May 31;9(5):2200–2206. doi: 10.4103/jfmpc.jfmpc_111_20.
2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013.
3. Egorov EA, Egorov AE, Eliseeva TO, Egorova TE. Undesirable effects of hypotensive treatment of glaucoma. Literary review. Russian Journal of Clinical Ophthalmology. 2011;12(3):111 –113 (In Russ).
4. Kiseleva OA, Yakubova LV, Bessmertny AM. Beta-blockers in the treatment of glaucoma: history and prospects. Effective pharmacotherapy. Ophthalmology. 2018;2:4–17 (In Russ).
5. Astakhov YS, Nechiporenko PA. Prostaglandin analogues: past, present, and future. Ophthalmology journal. 2017;10(1):40–52 (In Russ).